(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 2. Severe placental defects in
c-myc
ORF
/ORF
embryos. (A) Immunohistochemical analysis of c-Myc expression in
the E10.5 wild-type placenta. c-Myc expression is detected in the embryonic
parts of the placenta, including the chorionic plate (CP), labyrinth layer
(La), spongiotrophoblast (Sp), trophoblast giant cells (TGC) and in
hematopoietic cells derived from the embryo, which are located in the fetal
blood spaces (inset A'). (B-D) Comparison of control (left) and c-Myc
null
(c-myc
ORF/
ORF)
embryos (right) at E10.5. (B) Hematoxylin and eosin (H&E) staining
of control and c-Myc-deficient placenta at E10.5. The bottom panels show an
enlargement of the boxed areas in the top panels. (C) Analysis of
placental vascularization. Laminin (pink) is expressed on embryonic vessels
and defines fetal blood spaces. Cytokeratin (brown) marks trophoblast cells
and defines maternal blood spaces. The bottom panels show an enlargement of
the boxed areas in the top panels. The white line demarcates the failure of
vessels (pink) to invade into the trophoblast (brown) layer (D)
Bromodeoxyuridine (BrdU) incorporation analysis of E9.5 control and
c-Myc-deficient placenta. Highly proliferating (BrdU+; arrows) tissues are
present in control (left) but not in
c-myc
ORF/
ORF
(right) placentas. (E) Hematoxylin and eosin (H&E) staining of
control and
Sox2Cre;c-mycflox/flox
placenta at E10.5. Placental developmental defects are rescued with respect to
c-myc
ORF/
ORF
in B.